Veterinary
Cancer Therapeutics, LLC
The immune system holds the key to effectively fighting cancer and inducing long term tumor immunity. The most effective new cancer treatments will come from optimizing the immune response against cancer, the reason we are developing immune based strategies versus drug approaches.
Veterinary Cancer Therapeutics, a subsidiary of IMULAN BioTherapeutics, was formed to advance IMULAN’s core technologies for veterinary oncology. We are currently developing an autologous method to induce tumor specific antigen immunity; a patient specific approach to oncology.
More information will be available soon regarding the new technologies we are advancing for veterinary medicine.
IMULAN is focused
on providing innovative
solutions for complex
animal diseases.
Our policy is to provide
veterinarians access to
conditionally approved
products for diseases,
such as FeLV and FIV,
where no current
approved therapy
is available.
*Lymphocyte T-Cell Immunomodulator has received a conditional license from the United States Department of Agriculture. Additional efficacy
and potency studies are in progress. LTCI is manufactured by T-Cyte Therapeutics, Inc. and is exclusively distributed by IMULAN.
